|1.||Wahab, M: 3 articles (12/2001 - 03/2000)|
|2.||Spielmann, D: 2 articles (09/2005 - 08/2005)|
|3.||Thompson, J: 2 articles (12/2001 - 03/2000)|
|4.||Al-Azzawi, F: 2 articles (09/2001 - 03/2000)|
|5.||Gaillard-Kelly, M: 2 articles (08/2001 - 02/2001)|
|6.||Silva, Betania Huber: 1 article (12/2011)|
|7.||Wender, Maria Celeste Osório: 1 article (12/2011)|
|8.||Martinez, Denis: 1 article (12/2011)|
|9.||Collaço, Luiz Martins: 1 article (07/2011)|
|10.||Lago, Vanessa Vieira Dal: 1 article (07/2011)|
05/01/2004 - "To determine the efficacy of estrogen + progestogen therapy with 1 mg 17beta-estradiol and 0.125 mg trimegestone in the prevention of postmenopausal osteoporosis. "
08/01/2001 - "Trimegestone is a novel norpregnane progestin, which is being developed, in combination with 17 beta-estradiol, for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis. "
05/01/2002 - "The objectives of this study were to test the effect of changing the dose of trimegestone and the duration of treatment on the pattern of bleeding in these women who then entered a 6 month extension phase where a single dose of trimegestone was given sequentially combined with E(2). "
09/01/1997 - "To study the effects of oral trimegestone on endometrial histology and vaginal bleeding when given in combination with oral 17-beta-oestradiol. "
05/01/2002 - "The dose of trimegestone, and not the duration of treatment, appears to be the important determinant of the pattern of bleeding in post-menopausal women on this HRT regimen."
05/01/2002 - "Women who previously received trimegestone doses of 0.05 and 0.1 mg experienced a later onset of bleeding, which was lighter and of shorter duration (P < 0.001) during the extension phase as compared with the first 6 months. "
05/01/2002 - "Women who had received trimegestone 0.25 mg/day during the first 6 months experienced no change in the bleeding pattern in the 6 month extension. "
|3.||Uterine Hemorrhage (Uterine Bleeding)
03/01/1999 - "In this multicentre dose-ranging study using randomized parallel groups, four doses of trimegestone were used to compare data on the patterns of uterine bleeding, the endometrial histology, and the control of menopausal symptoms in 203 women who completed treatment for 6 months. "
03/01/1999 - "Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study."
03/01/2000 - "The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy."
|4.||Sleep Initiation and Maintenance Disorders (Insomnia)
08/01/2001 - "A model of osteoporosis in the ovariectomized rat has been used to evaluate the effects of 17 beta-estradiol and trimegestone, alone and in combination, on bone and uterus in these animals. "
02/01/2001 - "The effects of trimegestone (1 mg/kg/day orally), a novel norpregnane progestin, and 17 beta-estradiol (10 micrograms/kg/day subcutaneously), alone and in combination, on bone mass and turnover were investigated using an experimental model of osteoporosis involving ovariectomized rats. "
|3.||norethindrone acetate (Norlutate)
|5.||estradiol valerate (Delestrogen)
|6.||Progesterone Receptors (Progesterone Receptor)
|9.||Medroxyprogesterone Acetate (Depo-Provera)
|10.||Levonorgestrel (Plan B)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)